65,437 trials
Catheters, With or Without Malposition · Image Interpretation, Computer Assisted
Primary: Time for Completion of Tasks — 27.68; 22.90 seconds
Erythema · Rosacea
Primary: Composite Success — 14.3; 5.7 percentage of subjects
Secondary Hyperparathyroidism · Chronic Kidney Disease Stage V · Cardiac Morbidity
Primary: Percentage of Participants Achieving an Intact Parathyroid Hormone (iPTH) Level Within the Target Range — 28.4; 43.3; 35.8; 38.8 percentage of participants
Non-Small Cell Lung Cancer
Primary: Time to Disease Progression or Death by Line of Treatment — 3.4; 4.7; 2.7; 3.9 months
Insomnia
Primary: Average Total Sleep Time (TST) as Recorded Daily in the Sleep Diary During the 14-day In-treatment Period — 382.14; 382.77; 394.83; 351.40 Minutes — p=<0.0001
Rheumatoid Arthritis
Primary: Percentage of Participants With Adverse Events — 48.8; 10.7; 8.3; 5.8 percentage of participants
Non-small Cell Lung Cancer
Primary: Progression-free Survival — 8.95 Months
Myelodysplastic Syndrome (MDS) · Acute Myeloid Leukemia (AML) · Chronic Myeloid Leukemia (CML)
Primary: Number of Participants Who Experienced Inducing or Boosting of a Cellular Immune Response — 5; 2 participants
Endothelial Dysfunction · Hypertension
Primary: Change in Systolic Blood Pressure to After Completing an 8-hour Normal Saline Infusion in Obese Normotensive Subjects. — 13 mmHg
Uveitis
Primary: Number of Eyes With Inflammation Recurrence — 1 eye with inflammation
Bronchiectasis
Primary: 24 Hour Sputum Volume — 41.8; 23.6; 29.9; 26.2 gram — p=<0.01
Irritable Bowel Syndrome · Generalized Anxiety Disorder
Primary: Clinical Global Impression Scale — 2.64 scores on a scale
Chronic Kidney Disease
Primary: Number of Participants With Serious Adverse Drug Reactions (SADR), Serious Adverse Events (SAEs) or Events of Medical Interest (EMIs) — 4; 162; 39 participants
Coronary Artery Bypass Surgery · Elective Surgical Procedure
Primary: Endothelial Progenitor Cells (EPCs) Count (Cells/µl) — 5.00; 2.19 cells/µl
Leukemia, Myeloid
Primary: Response Rate (CR + CRi + LFS) — 3; 10 participants